Cardiac Calcification in ESRD: New Information Revealed

ASN/ISN Satellite Symposium. San Francisco, CA. October 13, 2001
Access to this program is free but HDCN free zone registration is required.
A Welcome and Introductory Remarks
Eduardo Slatopolsky, MD, FACP.
Molecular Aspects of Vascular Calcification
Cecilia M. Giachelli, PhD.
Slowing the Progression of Cardiac Calcification
Glenn M. Chertow, MD, MPH.
Non-Invasive Screening for Cardiac Calcification
Paolo Raggi, MD, FACP, FACC.
Panel Discussion
Eduardo Slatopolsky, MD, FACP, and Panel

After participating in this activity, participants should be able to:

Characterize the development and consequences of hyperphosphatemia;
Understand how to balance phosphorus and calcium in patients with ESRD;
Recognize the impact of hyperphosphatemia on vascular and cardiac calcification: and
Describe methods and therapies and recognize their clinical significance for hyperphosphatemia.

Glenn M. Chertow, MD, MPH
Associate Professor of Medicine
University of California, San Francisco
School of Medicine
San Francisco, California

Cecilia M. Giachelli, PhD
Associate Professor of Bioengineering
University of Washington
Seattle, Washington

Paolo Raggi, MD, FACP, FACC
Associate Professor of Medicine
Director of Noninvasive and Preventive Cardiology
Tulane University School of Medicine
New Orleans, Louisiana

Eduardo Slatopolsky, MD, FACP
Joseph Friedman Professor of Renal Disease in Medicine
Washington University of St. Louis
St. Louis, Missouri



Post-test and evaluation form are at this link, but you must listen to all talks from this symposium prior to completing the test.
CME: The University of Minnesota is accredited by the Accreditation Council for Continuing Medical Education (AACME) to sponsor continuing medical education for physicians.
The University of Minnesota designates this educational activity for up to 1.5 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity.

CEU: These talks are also designated to provide 1.5 hours of CEU nursing education credits, sponsored by the Renal Education Association. The Renal Education Association is accredited by the State of California Board of Nursing to provide continuing education for nurses (provider number: CEP 13092).

Posting date: June 27, 2002.
Review date: June 27, 2003

Participation in this self-study activity should be completed in approximately two (1.5) hours. There are no fees for participating and receiving CME or CEU credit for this activity. To successfully complete this activity and receive credit, participants must follow these steps during the period June 27, 2002 through June 27, 2003.
1. Register for continuing education credit by completing the registration process.
2. Read the goals and learning objectives.
3. Read the article text and tables, and review figures.
4. Read, complete, and submit answers to the post test questions and evaluation questions. You must receive a test score of at least 75% and respond to all evaluation questions to receive your online CME or CEU certificate.

The primary target audience is physicians involved in the care of renal patients (CME), and nephrology nurses, dialysis technicians and pharmacists (CEU).

All faculty participating in continuing medical education programs are expected to disclose to the program audience any real or apparent conflict of interest related to the subject under discussion. The faculty disclosure information is as follows:
Glenn M. Chertow, MD, MPH, receives grant support and honoraria from Genzyme Therapeutics and Amgen. He is also a physician advisory board member for Genzyme Therapeutics and Amgen
Cecilia M. Giachelli, PhD, indicates no relevant affiliations or financial interest or arrangements.
Paolo Raggi, MD, FACP, FACC, receives grant support and honoraria from Genzyme Therapeutics and is a stockholder in Pfizer Inc. Dr. Raggi’s presentation will include off-label or investigational use of a drug.
Eduardo Slatopolsky, MD, FACP, consults for Chugai, Abbott Laboratories, and Genzyme Therapeutics. He has received grant support from Geltex and honoraria from Abbott Laboratories and Genzyme Therapeutics. He is also a stockholder in Merck and Amgen. Dr. Slatopolsky’s presentation will include off-label or investigational use of a drug
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The University of Minnesota, ASN, HDCN and the Renal Education Association do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

This educational activity is supported by an educational grant from Genzyme Therapeutics
This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies and with CE policies of the State of California Board of Registered Nursing.
This educational activity is based on an official ASN/ISN satellite symposium.
It was not organized by the World Congress of Nephrology Program Committee.